


## **Supplementary to Manuscript**

### **Vaccination with BNT162b2 and ChAdOx1 nCoV-19 induce cross-reactive anti-RBD IgG against SARS-CoV2 variants including Omicron**

**Daniela Gerges<sup>1</sup>, Sebastian Kapps<sup>1</sup>, Esperanza Hernández<sup>2,3,4</sup>, Raimundo Freire<sup>2,3,4</sup>,  
Monika Aiad<sup>1</sup>, Sophie Schmidt<sup>1</sup>, Wolfgang Winnicki<sup>1</sup>, Thomas Reiter<sup>1</sup>, Sahra Pajenda<sup>1</sup>,  
Alice Schmidt<sup>1</sup>, Gere Sunder-Plassmann<sup>1</sup>, and Ludwig Wagner<sup>1\*</sup>**



**Supplementary Figure S1.** RBD IgG cross-reactivity at the pre-pandemic testing and increase of IgG reactivity against Alpha, Gamma, and Delta RBD following vaccination with the BNT162b2 or ChAdOx1 nCoV-19 vaccines.